Oric Pharmaceuticals’ Promising Study on ORIC-944 for Metastatic Prostate Cancer

Oric Pharmaceuticals Inc ((ORIC)) announced an update on their ongoing clinical study.

Study Overview: Oric Pharmaceuticals Inc is conducting a study titled An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer. The study aims to assess the safety and preliminary antitumor activity of ORIC-944, either alone or in combination with other drugs, in patients with metastatic prostate cancer. This research is significant as it explores potential new treatment options for a challenging condition.

Intervention/Treatment: The study tests ORIC-944, an oral drug administered daily, both as a single agent and in combination with other androgen receptor pathway inhibitors like abiraterone, apalutamide, darolutamide, and enzalutamide. These combinations aim to enhance treatment efficacy for metastatic prostate cancer.

Study Design: The study is interventional, using a non-randomized, sequential model with a 3+3 dose escalation design. There is no masking, meaning all participants and researchers know the treatments being administered. The primary purpose is treatment-focused, aiming to identify effective dosing and safety profiles.

Study Timeline: The study began on June 7, 2022, with the latest update submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.

Market Implications: This study update could positively influence Oric Pharmaceuticals’ stock performance by showcasing their commitment to innovative cancer treatments. Successful outcomes may enhance investor confidence and position Oric favorably against competitors in the oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.